Finacea and Finacea Foam (Azelaic Acid 15%)
One of the best known topicals to treat the papules and pustules of rosacea is Finacea. Finacea is Azelaic Acid 15%. Finacea is only available on prescription in the US but is available over the counter in Australia. Be sure to check out the Finacea User Reviews and also the recently approved Finacea Foam product.
Recent Rosacea Blog Posts

LeoPharma has announced that FinaceaFoam is back again after some availability issues. So if you have not been able to fill your prescription for Finacea Foam, it should be possible to do so now. LEO Pharma Inc. Announces Availability of Finacea® (azelaic acid) Foam, 15%, for Treatment of Mild-to-Moderate Rosacea Madison, N.J., April 15, […]

News today that Glenmark Pharmaceutiacals has received approval from the FDA to manufacture a generic form of Azelaic Acid Gel 15% (marketed under the name Finacea). There has been quite a bit of business activity related to Finacea in the last year. Indeed back in 2013 we learnt that Bayer HealthCare the makers of Finacea, […]

News today that Bayer HealthCare is selling its prescription dermatology business to the unlisted Danish company Leo Pharma. Leo Pharma now becomes an interesting company for rosacea sufferers given the prevalence and efficacy of both Finacea and Finacea Foam. The future of these products and any related funded research now rests with Leo Pharma. LEO […]

Does the trip to the doctor, taking the paperwork to the chemist and then negotiating the insurance minefield get you down? Well you are not alone – many rosacea sufferers despair at how much it takes to get hold of your favourite prescription treatment. Well what would it take for the rosacea treatment main stays […]

A recent press release from Foamix gives a view into how well Finacea Foam is selling. Based on Q1 2016 sales of the newly approved Finacea Foam, Bayer HealthCare made a royalty payment of $682,000 to Foamix as a fee for licensing their foaming technology. Along with the comment that Finacea Foam sales are continuing […]